Travere Therapeutics Inc (TVTX) Cumulative Dividend Pay out History TTM by Quarter, Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 
• Dividend Growth
• Cumulative Pay out
Travere Therapeutics Inc   (NASDAQ: TVTX)

 

TVTX's Dividend Pay out ratio over the 12 Months Period

Cumulative by Quarter, Trailing twelve months

Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.



According to the latest data Jun 30 2026, it is not possible to calculate dividend pay out ratio.
Visit Travere Therapeutics Inc Cash flow


Dividend in Glossary



Back to TVTX Dividend Comparisons >> See also TVTX's dividend growth by quarter >> See also TVTX's eps growth
Cumulative Dividend Pay out Ratio II. Quarter
(Jun 30 2026)		 I. Quarter
(Mar 31 2026)		 IV. Quarter
(Dec 31 2025)		 III. Quarter
(Sep 30 2025)		 II. Quarter
(Jun 30 2025)
TVTX's Pay out Ratio (TTM) - - - - -
TVTX's Dividend Pay out Ratio Total Ranking # # # # #

  News about Travere Therapeutics Inc Dividends

Travere Therapeutics Raises $125 Million to Propel Innovations in Kidney Disease Treatment

San Diego, CA ?? In a decisive move signaling its strong position in the biopharmaceutical industry, Travere Therapeutics, Inc. (Nasdaq: TVTX) has announced an underwritten public offering of its common stock, pricing 7,812,500 shares at a public offering price of $16.00 each. This bold initiative, which is anticipated to yield gross proceeds of approximately $125 million, is a critical milestone for Travere as it seeks to bolster its financial resources and further its mission to develop transformative therapies for rare kidney diseases.The offering, expected to close on November 12, 2024, is set against the backdrop of the recent approval Travere received for its innovative kidney disease treatment. Just weeks earlier, on October 17, 2024, Travere along with their partner CSL Vifor announced the approval of FILSPARI by Swissmedic, the Swiss Agency for Therapeutic Products, specifically for the treatment of IgA nephropathy. This significant advancement not only highlights the company's commitment to addressing unmet medical needs but also enhances its competitive edge in an increasingly dynamic market.

TVTX's Dividend Pay out Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
S&P 500 #

Dividend Pay out Ratio Statistics
High Average Low
0 % 0 % 0 %
 



Other Dividend Ratios
Highest Ranking Dividend Yield
Lowest Ranking Dividend Yield
Annual Dividend Pay out for TVTX
TVTX's Dividend Yield




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.